Table 5.

Distribution of prescribed doses at the index date in the Price et al. [77] and Barnes et al. [78] 2-way matched analyses of EF HFA-BDP vs FP, and EF HFA-BDP vs CFC-BDP^a

		Initiation population		Step-up population
QVAR vs BDPb (Fig. 1b)		EF HFA-BDP (N = 2,882)	CFC-BDP (N = 2,882)	EF HFA-BDP (N = 258)	FP (N = 258)
Distribution of patients by mean ICS dose prescribed at the index date,%	1–199 μg/d	30	1.1	2.3	0.0
	200–399 μg/d	60.3	12.9	39.1	2.5
	400–799 μg/d	19.0	69.0	65.4	33.5
	800–1,199 μg/d	1.0	16.0	3.1	57.8
	≥1,200 μg/d	0.0	1.1	0.0	6.2
QVAR vs FP (Fig. 1b)		EF HFA-BDP (N = 1,319)	FP (N = 1,319)	EF HFA-BDP (N = 250)	FP (N = 250)
Distribution of patients by mean ICS dose prescribed at the index date,%	0–99 μg/d	0.0	5.5	0.0	0.0
	100–199 μg/d	29.8	18.7	1.6	1.6
	200–299 μg/d	50.2	35.9	32.1	24.3
	300–399 μg/d	0.3	0.3	0.5	0.7
	400–599 μg/d	18.9	28.4	59.3	42.9
	600–799 μg/d	0.2	0.1	1.1	0.7
	≥800 μg/d	0.7	10.9	5.2	29.7

^aPrescribed doses were significantly lower for both the initiation and step-up EF HFA-BDP populations across both studies (P < 0.001)

^bDaily ICS dose during the outcome year was calculated as the dispensed amount divided by 365 (the licensed dose of EF HFA-BDP dose is ~50% that of CFC-BDP)

BDP beclomethasone dipropionate, CFC-BDP chlorofluorocarbon beclomethasone dipropionate, EF HFA-BDP extra-fine hydrofluoroalkane beclomethasone dipropionate, FP fluticasone propionate, ICS inhaled corticosteroid